In vitro synergy studies with Clostridium difficile.
Agar dilution anaerobic susceptibility studies using rifampin, vancomycin, metronidazole, and bacitracin individually and in combination were performed with Clostridium difficile. Fifty-five strains of C. difficile were studied. Eighty-five percent of strains tested (29 of 34) were synergistically inhibited by the combination of bacitracin and rifampin (fractional inhibitory concentration, less than or equal to 0.50).
Bacon
A E
AE
Department of Medicine, Medical Center of Delaware, Wilmington 19899.
McGrath
S
S
Fekety
R
R
Holloway
W J
WJ
D001414:Bacitracin / Q000494:pharmacology*; D016360:Clostridioides difficile / Q000187:drug effects*; D004338:Drug Combinations; D004357:Drug Synergism; D006801:Humans; D008795:Metronidazole / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D012293:Rifampin / Q000494:pharmacology*; D014640:Vancomycin / Q000494:pharmacology*
D004338:Drug Combinations; D001414:Bacitracin; D008795:Metronidazole; D014640:Vancomycin; D012293:Rifampin